Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
06:40pm, Monday, 29'th Apr 2024
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
06:40pm, Monday, 29'th Apr 2024
NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics L
Transactions in Connection with Share Buy-back Program Genmab
04:24am, Monday, 29'th Apr 2024
Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billi
Transactions in Connection with Share Buy-back Program Genmab
03:30am, Monday, 22'nd Apr 2024
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billi
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
06:24am, Tuesday, 16'th Apr 2024
Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, De
Transactions in Connection with Share Buy-back Program Genmab
04:07am, Monday, 15'th Apr 2024
Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billi
Transactions in Connection with Share Buy-back Program
05:44am, Monday, 08'th Apr 2024
Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billio
Biotech giant Genmab to acquire Seattle company ProfoundBio in $1.8B deal
11:28am, Wednesday, 03'rd Apr 2024
ProfoundBio, a Seattle-based biotech firm developing drugs to treat ovarian and endometrial cancers, will be acquired by publicly traded Danish drugmaker Genmab in a $1.
Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio
09:20am, Wednesday, 03'rd Apr 2024
Danish drugmaker Genmab A/S (GMAB) said Wednesday that it is buying privately held U.S. biotech firm ProfoundBio Inc. for $1.8 billion in cash as it expands its pipeline of cancer treatments.
Denmark's Genmab to acquire ProfoundBio for $1.8 billion
03:47am, Wednesday, 03'rd Apr 2024
Danish biotech Genmab has agreed to buy U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
01:35am, Wednesday, 03'rd Apr 2024
COPENHAGEN, Denmark & SEATTLE--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab to acquire Profou
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
01:34am, Wednesday, 03'rd Apr 2024
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:56am, Friday, 19'th Jan 2024
After losing some value lately, a hammer chart pattern has been formed for Genmab A/S Sponsored ADR (GMAB), indicating that the stock has found support. This, combined with an upward trend in earnings
New Strong Buy Stocks for January 17th
08:16am, Wednesday, 17'th Jan 2024
SKWD, PHG, BK, PAGS and GMAB have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2024.
Genmab: 3 Trends To Track For A Strong 2024 And Beyond
11:20pm, Thursday, 11'th Jan 2024
Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown
